FIRST's Pivotal Role in the Ichthyosis With Confetti Story Newborn and early childhood complications and comorbidities that accompany the ichthyoses. Gene Therapy and Rare Disease  

Topical Tazarotene for treatment of ectropion in ichthyosis Topical Delivery of Keratin 10 Bathing Completes the Shedding Process...naturally  
Studies on novel therapeutic options for epidermolytic ichthyosis affecting the skin barrier Generating immortalized cell lines and iPS cells from EHK patients Ichthyosis Incidence Study  

Surveys of the ichthyosis community, specifically individuals affected with ichthyosis and their families, have indicated that research is the primary area of interest and a top priority for funds donated to FIRST.  Research is fundamental to our mission. Over the years, investigators have made novel advances into the causes and treatments for the ichthyoses. 

FIRST has a proud history of funding research. For many years, FIRST funded research through the Dermatology Foundation. The Dermatology Foundation is a well-respected nonprofit organization, that is second only to the National Institutes of Health in the funding of dermatological research.  To stimulate more interest and provide a focused direction, FIRST officially launched its own Research Grant Program in 2006. This program promotes and strengthens investigation into the causes, treatments, and potential cures for ichthyosis. Summaries of the many projects that have been funded by FIRST are available. 

In addition to the projects FIRST has funded, additional research articles about ichthyosis-related research are available.

2015 FIRST Research Times Newsletter

Current Patient Recruitment Opportunities

Darier-White / Hailey-Hailey disease Indiana University Research Center
X-linked males study Cardiff University
Harlequin ichthyosis medical records study Boston Children's Hospital
Study for Sjogren-Larsson syndrome Omaha, NE / Portland,OR / Pittsburgh, PA
Gene Discovery Opportunity Yale University
Itch study Temple University Dermatology
Newborn Study Yale University
NS2 Compound for Sjogren-Larsson Syndrome Aldeyra Therapeutics


« Back to Previous Page